Hudson Institute of Medical Research

First-in-Human Trial Launches for Novel Extracellular Vesicle Therapy in Crohn's Fistulas

3 months ago

• Hudson Institute researchers advance groundbreaking extracellular vesicle treatment derived from amniotic cells into clinical trials for complex perianal Crohn's disease, offering a potential cost-effective alternative to stem cell therapy. • The first-in-human trial will evaluate the safety and efficacy of hAEC-EV therapy in 15 participants with refractory Crohn's perianal fistulas, marking the second human EV trial in Australia. • With the global Crohn's disease market projected to reach $13.4 billion by 2026, this innovative approach could provide a more accessible treatment option for the one-third of patients who develop fistulas.

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial with INV043

6 months ago

• Invion has dosed the first patient in its Phase I/II trial evaluating topical INV043 for non-melanoma skin cancer (NMSC). • The open-label, adaptive trial will assess the safety and efficacy of INV043 in cutaneous Squamous Cell Carcinoma and superficial Basal Cell Carcinoma. • Preclinical data suggests INV043 may offer advantages over current NMSC treatments, such as efficacy without scarring and minimal pain. • Invion plans to leverage data from this trial into a Phase II anogenital cancer trial, potentially including immune checkpoint inhibitors.